Clostridium difficile presence in Spanish and Belgian hospitals
Introduction
Clostridium difficile is currently one of the most largely studied pathogenic bacteria in the world and is considered as the major cause of nosocomial antibiotic-associated diarrhoea and colitis in industrialised countries [1]. Clinical manifestations of C. difficile infection (CDI) range from mild or moderate diarrhoea to fulminant and sometimes fatal pseudomembranous colitis [2]. Normally, the diarrhoea has been described to appear 48–72 h post infection and characterised as non-haemorrhagic and watery, accompanied with abdominal pain, fever and leucocytosis [3]. However, the worst outcomes are sepsis and death, which is observed in 17% of CDI cases [4]. The highest incidence and mortality rate is usually reported among patients of advanced age who have had a stay in a healthcare setting [5].
A recent review of CDI cost-of-illness attributes a mean cost ranging from $8911 to $30,049 per hospitalised patient in the USA [6] and around €3000 million total per annum in Europe [7]. In addition, in many hospitals the diagnosis strategy remains suboptimal and a proportion of infections may remain undiagnosed [8]. In the past decade, an increase in the incidence and severity of the infection has been reported in various healthcare settings among many countries [9]. This situation was attributed to the emergence of a new epidemic and hypervirulent C. difficile strain, identified as PCR-ribotype 027 (NAP1 or North American pulsed field type 1) [10]. Since 2003, in the United States and Canada, studies have shown an increase in the number and severity of CDI cases, including an increase in the case fatality, mortality and colectomy rates [11]. The situation presented by studies in North America is mirrored in Europe. In 2008, the PCR-ribotype 027 was detected in 16 European countries and caused outbreaks in Belgium, Germany, Finland, France, Ireland, The Netherlands, Switzerland and the United Kingdom [11], [12]. However, in a further epidemiology study conducted in Europe, the most prevalent PCR-ribotypes were identified as 014/020 (15%), 001 (10%) and 078 (8%), while PCR-ribotype 027 was less prevalent (5%) [12]. Surveillance data for Belgium from 2008 to 2010 showed a stable incidence of CDI in Belgian hospitals, and even a decrease in 2010. In addition, PCR-ribotype 027 was the most prevalent type during the years 2007–2009 [13]. A further study reporting CDI ribotype distribution in Belgian hospitals between 2008 and 2010 described a decrease in cases caused by PCR-ribotype 027 (from 55% in 2008 to 28% in 2010). In contrast, the proportion of other PCR-ribotypes involved in CDI increased, such as ribotype 014 (from 20% in 2008 to 33% in 2010) and ribotype 078 (from 11% in 2009 to 23% in 2010) [14]. Meanwhile, a prospective study conducted in 2009 in the region of Barcelona (Spain) identified the main PCR-ribotypes associated with CDI as 241 (26%), 126 (18%), 078 (7%) and 020 (5%), while PCR-ribotype 027 was not detected [15]. In a later study conducted in the region of Madrid (Spain) from January to June 2013, most of the isolates associated with a CDI case possessed binary toxin and were classified as PCR-ribotype 078/126 (90.7%) [16]. Consistent with these reports, Weber et al. [17] studied C. difficile clinical isolates recovered at the reference hospital of the Balearic Islands (Spain) between August 2007 and April 2011. The authors detected a total 43 different PCR-ribotypes with a higher prevalence of types 014 (34%), 078 (13%) and 001 (5%). As in other Spanish studies, none of the isolates were identified as PCR-ribotype 027.
The aim of this study was to survey the C. difficile circulation during the summer of 2014 at the Central University Hospital of Asturias (Spain), a provincial hospital located in the North of Spain. By typing of all the isolates obtained, it was then possible to compare the ribotype distribution at the Spanish hospital with results from the St Luc University Hospital in Belgium over the same period.
Section snippets
Hospital selection, data and sampling
The Central University Hospital of Asturias (HUCA) located in Oviedo (Asturias, Spain), is the referral hospital of the Health Service of the Principality of Asturias. Overall, the hospital has 17 buildings with a total of 1324 beds, 29 operating rooms, 203 consultation rooms (for outpatients) and 123 emergency rooms.
During the 4-month period from July to October 2014, all samples from outpatients and hospitalised patients suspected of being infected with C. difficile were tested. Stool
C. difficile detection and strain characterisation in HUCA, Spain
During the four-month study period, a total of 249 samples were screened for C. difficile presence using both the rapid enzyme test and culture analysis. Twelve additional samples were only examined by culture because they were classified outside of the range established (between 4 and 7) on the BSC. The overall prevalence of C. difficile in the faecal microbiota of patients studied was 12.3% (32/261). Of these, 69% were from adults aged more than 65 years old. Only following clinical
Discussion
C. difficile continues to be the most common cause of healthcare-associated infection in the developed world. A previous European C. difficile infection hospital-based survey has shown that the incidence of CDI and the distribution of causative PCR-ribotypes differed greatly between hospitals [21]. In Spain, the number of toxin-positive cases reported varied between 5.5% and 5.6% (2008) [22], 9% (2008) [21] and 6.0%–6.5% (2013) [22]. In this study the prevalence was higher than has been
Financial support
This research received no specific grant from any funding agency, commercial or not-for-profit sectors.
Declaration of interest
None.
Acknowledgements
The authors offer their most sincere thanks to the microbiology laboratory service of HUCA as well as to the microbiology unit of St Luc Hospital for technical support.
This study was presented at the 5th International Clostridium difficile Symposium (5th ICDS 2014), Bled, Slovenia, May 19–21, 2014.
References (34)
- et al.
Clostridium difficile: an emerging epidemic in nursing homes
Geriatr. Nurs. (New York, NY)
(2007) - et al.
Clostridium difficile: a European perspective
J. Infect.
(2013) Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain
Int. J. Med. Microbiol.
(2013)Clostridium difficile in young farm animals and slaughter animals in Belgium
Anaerobe
(2012)Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing
FEMS Microbiol. Lett.
(1999)Clostridium difficile infection in Europe: a hospital-based survey
Lancet London Engl.
(2011)- et al.
Pitfalls in diagnosis of pediatric Clostridium difficile infection
Infect. Dis. Clin. N. Am.
(2015) Clostridium difficile isolation in children hospitalized with diarrhea. Anales de Pediatría (Barcelona, Spain: 2003)
(2015)Clostridium difficile infection and intestinal microbiota interactions
Microb. Pathog.
(2015)Investigation of a cluster of Clostridium difficile infections in a pediatric oncology setting
Am. J. Infect. Control
(2016)
Clostridium difficile: from obscurity to superbug
Br. J. Biomed. Sci.
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Infect. Control Hosp. Epidemiol.
High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany
PloS One
The economic impact of Clostridium difficile infection: a systematic review
Am. J. Gastroenterol.
Clostridium difficile infections: do we know the real dimensions of the problem?
Int. J. Antimicrob. Agents
Current trends in the epidemiology and outcomes of Clostridium difficile infection
Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.
Cited by (7)
Impact of the COVID-19 pandemic on Clostridioides difficile infection in a tertiary healthcare institution in Belgium
2023, Acta Clinica Belgica: International Journal of Clinical and Laboratory MedicineImpact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
2022, FEMS Microbiology LettersToxin profiles and antimicrobial resistance patterns among toxigenic clinical isolates of Clostridioides (Clostridium) difficile
2019, Iranian Journal of Basic Medical SciencesGeneration of markerless deletions in the nosocomial pathogen Clostridium difficile by induction of DNA double-strand breaks
2019, Applied and Environmental Microbiology